Volume 11, Issue 2 (10-2016)                   bjcp 2016, 11(2): 23-35 | Back to browse issues page

XML Persian Abstract Print


1- Allameh Tabataba'i University
2- Allameh Tabataba'i University , asmar567@yahoo.com
Abstract:   (6361 Views)
Obsessive compulsive disorder is one of the most common psychological disorders that has a great impact on performance and quality of life of patients. The aim of this study was to investigate the effectiveness of metacognitive therapy in group and individual design on obsessive-compulsive and depressive symptoms in patients with obsessive-compulsive disorder. 30 patients with obsessive-compulsive disorder, subsequent to primary clinical assessment and obtaining study requirements were selected and randomly assigned to individual therapy (n = 10), group therapy (n = 10) and control group (n = 10). The experimental groups received 10 metacognitive therapy sessions on a weekly basis. Data collection tool was Yale –Brown Obsessive Compulsive Scale (Y-BOCS) and Beck Depression Inventory (BDI-II), which was performed in pretest, posttest and one month follow up. Results showe that metacognitive therapy in group and individual design are effective in reducing of obsessive-compulsive and depression symptoms and metacognitive therapy in comparison with the control group causes significant reduction in obsessive-compulsive and depression symptoms in the patients at the post-test stage. There was no significant difference between group therapy and individual therapy. Therapeutic achievements were maintained at the follow-up stage. Based on the results of this study, metacognitive therapy is effective in the treatment of obsessive-compulsive disorder and can be used in a group and individual design to treat obsessive-compulsive disorder.
 
Full-Text [PDF 556 kb]   (3270 Downloads)    
Type of Study: Research | Subject: Special
Received: 2017/08/16 | Accepted: 2018/01/16 | Published: 2018/01/16

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.